Efficacy of canakinumab as first-line biologic agent in adult-onset Still’s disease

Giulio Cavalli 1,2,3*, Alessandro Tomelleri 1,2, Giacomo De Luca 1,2, Corrado Campochiaro 1, Charles A. Dinarello 3,4, Elena Baldissera 1 and Lorenzo Dagna 1,2

Adult-onset Still’s disease (AOSD) is a rare condition characterized by fever, arthritis, skin rash, and multi-organ inflammation. The pathogenesis is mediated by the pro-inflammatory cytokine interleukin (IL)-1β, as confirmed by the clinical efficacy of selective blockade. Anakinra, a recombinant inhibitor of the IL-1β receptor, currently represents the cornerstone of biologic therapy [1].

More recently, a monoclonal antibody blocking IL-1β, canakinumab, entered the clinical arena and became available for the treatment of AOSD. The efficacy of canakinumab in AOSD is being evaluated in a clinical trial (NCT022042939). At present, evidence from several case reports or series suggest good efficacy in AOSD (reviewed in [2, 3]): of note, in all published cases, canakinumab was used following failure of one or more biologics, including anakinra.

Here, we report the efficacy of canakinumab as a first-line biologic agent in AOSD. Four patients with severe DMARD-refractory AOSD received canakinumab (4 mg/kg/4 weeks) following failure of conventional treatment with corticosteroids and methotrexate. Patient characteristics and response to therapy are shown in Table 1. In all patients, treatment with canakinumab led to striking clinical responses, within days of initiation. Fever and skin rash disappeared first, followed by progressive improvement in arthritis. If present, inflammatory organ involvement also responded to treatment, as confirmed by resolution of pericardial inflammation and hepatosplenomegaly in two and one patients, respectively. Marked reductions in CRP, ESR, and serum ferritin mirrored the efficacy on clinical manifestations. Reduced disease severity allowed for robust tapering of corticosteroid therapy, which was discontinued in two patients and substantially reduced in two patients (Table 1).

Biologic therapy with IL-1 inhibitors should be instituted earlier in AOSD course for more favorable outcomes [2]. Both IL-1 blocking agents anakinra and canakinumab received EMA approval for the treatment of AOSD. Although anakinra and canakinumab block the same target, they have different mechanisms of action. Anakinra, a recombinant inhibitor of the IL-1 receptor, requires daily injections due to a short half-life of 6 h. Canakinumab, a fully human monoclonal antibody selectively blocking IL-1β, has a longer half-life and is administered monthly [4].

In this study, first-line biologic therapy of AOSD with canakinumab resulted in rapid and marked efficacy, ultimately leading to full clinical remissions in all patients and allowing for robust steroid-sparing effects. Canakinumab in AOSD is often used as a last line of treatment following failure of multiple other agents, including anakinra [2]. Early treatment is nevertheless advisable and may reduce chances of chronic disease and permanent damage [2, 5].

* Correspondence: cavalli.giulio@gmail.com
1 Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Via Olgettina 60, 20132 Milan, Italy
2 Vita-Salute San Raffaele University, Milan, Italy
3 Ecke, San Raffaele University, Milan, Italy
Full list of author information is available at the end of the article

© The Author(s). 2019, corrected publication 2019. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Abbreviations
AOSD: Adult-onset Still’s disease; CRP: C-reactive protein; DMARD: Disease-modifying anti-rheumatic drug; ESR: Erythrocyte sedimentation rate; IL-1β: Interleukin-1β

Acknowledgements
No individuals were involved besides those included in the Author list.

Data sharing
Not applicable to this article as no datasets were generated or analyzed during the current study.

Funding
GC has received funding from AIRC under MFAG 2018 - ID. 22136 project – PI Cavalli Giulio. CAD is supported by NIH grant AI-15614.

Authors’ contributions
GC, AT, GDL, CC, EB, and LD took care of patients; GC performed the statistical analysis and drafted the paper; CAD participated in the design of the study and helped to draft the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate
Need for approval waived as canakinumab is approved by Italian regulating bodies for the treatment of AOSD. Patients gave their consent to drug administration and utilization of data in anonymous form for research purposes.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Published online: 13 February 2019

References

Table 1 Patient characteristics and response to therapy

<table>
<thead>
<tr>
<th>Clinical features</th>
<th>AOSD course</th>
<th>Therapy before CAN (mg)</th>
<th>Lab tests before CAN</th>
<th>Therapy after CAN (mg)</th>
<th>Lab tests after CAN</th>
<th>Response to CAN</th>
<th>Modified Pouchot score before CAN</th>
<th>Modified Pouchot score after CAN</th>
<th>Side effect</th>
</tr>
</thead>
<tbody>
<tr>
<td>A, M, R, F, S</td>
<td>SD</td>
<td>PDN (15) MTX (20)</td>
<td>ESR 40 CRP 31.5 Ferritin 715</td>
<td>MTX (20) CRP 4.2 Ferritin 140</td>
<td>Complete 7 1 None</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A, M, R, F, HSM</td>
<td>SD</td>
<td>PDN (25) MTX (20)</td>
<td>ESR 45 CRP 8.2 Ferritin 880</td>
<td>PDN (5) MTX (15) CRP 3.7 Ferritin 135</td>
<td>Complete 6 2 None</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A, M, F, L, S</td>
<td>SD</td>
<td>PDN (10) MTX (10)</td>
<td>ESR 32 CRP 31.1 Ferritin 1324 –</td>
<td>–</td>
<td>Complete 5 1 None</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A, M, F, P, R</td>
<td>SD</td>
<td>PDN (25) MTX (20)</td>
<td>ESR 57 CRP 17.4 Ferritin 1025</td>
<td>PDN (2.5) MTX (5) CRP 2.1 Ferritin 119</td>
<td>Complete 6 1 None</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

AOSD duration indicates duration of disease before initiation of canakinumab (CAN). Disease manifestations: A arthritis; M myalgia; F fever; R rash; P pharyngitis; S serositis; L lymphadenopathies; HSM hepatosplenomegaly. Therapy before CAN indicates the treatment regimen that was being administered at the time of CAN initiation; therapy after CAN indicates the maintenance therapy that was being administered at the last follow-up visit. PDN prednisone; MTX methotrexate; SD systemic disease; ESR erythrocyte sedimentation rate (mm/1 h, normal values < 30 mm/1 h); CRP C-reactive protein (mg/L, < 6 mg/L); ferritin (ng/mL, 15–150 ng/mL). The modified Pouchot score for measuring AOSD disease activity evaluates clinical and laboratory manifestations and ranges from 0 to 12, with scores above 4 indicating active disease.